U.S. Patent Application Ser. No. 09/709,131 Response and Preliminary Amendment Filed in Response to Office Action Dated 11 February 2002

Amendments to the Claims

Please amend the claims to read as follows:

- 1-13. (Canceled)
- 14. (Withdrawn) An isolated polypeptide having an amino acid sequence which comprises at least about ten consecutive amino acid residues of SEQ ID NO: 8.
- 15. (Withdrawn) The isolated polypeptide of claim 14, wherein the sequence comprises at least about fifteen consecutive amino acid residues of SEQ ID NO: 8.
- 16. (Withdrawn) The isolated polypeptide of claim 14, wherein the sequence is SEQ ID NO: 8.
- 17. (Withdrawn) The isolated polypeptide of claim 16, wherein said polypeptide is substantially purified.
- 18-31. (Canceled)
- 32. (New) An antibody which binds with specificity to a portion of MCT-1.
- 33. (New) The antibody of claim 32, wherein the portion includes at least about ten consecutive amino acid residues of homologous residues 1-114 of SEQ ID NOs: 2 and 8.
- 34. (New) The antibody of claim 32, wherein the portion includes at least about ten consecutive amino acid residues of SEQ ID NO: 8.
- 35. (New) The antibody of Claim 32, wherein the portion includes amino acid residues 1-20 of SEQ ID NO: 8.
- 36. (New) The antibody of claim 32, wherein the antibody is substantially purified.
- 37. (New) The antibody of claim 32, wherein the antibody is a monoclonal antibody.

ATTORNEY DOCKET NO: D9498-00004

U.S. Patent Application Ser. No. 09/709,131 Response and Preliminary Amendment Filed in Response to Office Action Dated 11 February 2002

- 40. (New) A pharmaceutical composition comprising the antibody of claim 32 and a pharmaceutically acceptable carrier.
- 41. (New) A kit comprising the pharmaceutical composition of claim 40 and a reagent for detecting the antibody.
- 42. (New) A kit according to claim 44, further comprising instructional material which describes use of the suspension for at least one of inhibiting a tumor in a subject and treating a tumor in a subject.
- 43. (New) A kit according to claim 45, further comprising a device for administering the suspension to a subject.
- 44. (New) A method of making an antibody which binds with specificity to a portion of MCT-1, the method comprising immunizing a vertebrate with the portion of MCT-1 and thereafter isolating the antibody from the veterbrate.
- 45. (New) The method of claim 38, further comprising isolating antibody-forming cells from the spleen of the vertebrate and fusing the isolated cells with a tumor cell to form a hybridoma that secretes a monoclonal antibody that binds with specificity to the portion of MCT-1.
- 46. (New) A method of determining whether a cell is a tumor cell, the method comprising using the antibody of claim 32 to detect MCT-1 expression in the cell and comparing MCT-1 expression in the cell with MCT-1 expression in a non-tumor cell of the same type, whereby greater MCT-1 expression in the cell than in the non-tumor cell indicates the cell is a tumor cell.
- 47. (New) The method of claim 41, wherein the cell and the non-tumor cell are human cells.